Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XE38
|
| gptkbp:brand |
gptkb:Cotellic
|
| gptkbp:CASNumber |
934660-93-2
|
| gptkbp:chemicalFormula |
C21H21F3IN3O2
|
| gptkbp:combines |
gptkb:vemurafenib
|
| gptkbp:developedBy |
gptkb:Exelixis
gptkb:Genentech |
| gptkbp:genericName |
gptkb:cobimetinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cotellic
|
| gptkbp:indication |
melanoma
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Roche
|
| gptkbp:mechanismOfAction |
MEK inhibitor
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea rash photosensitivity liver toxicity |
| gptkbp:synonym |
gptkb:GDC-0973
gptkb:XL518 |
| gptkbp:bfsParent |
gptkb:Exelixis
gptkb:Roche |
| gptkbp:bfsLayer |
6
|